Back to top
more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$275.94 USD

275.94
179,207

+0.34 (0.12%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $275.92 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (140 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BIO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for BioRad Laboratories, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 1,613 1,796 875 997 1,120
Receivables 489 495 424 419 393
Notes Receivable 0 0 0 0 0
Inventories 781 719 572 622 554
Other Current Assets 166 148 118 101 113
Total Current Assets 3,048 3,158 1,989 2,140 2,180
Net Property & Equipment 529 499 491 491 499
Investments & Advances 7,698 8,831 14,387 9,561 4,638
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 734 739 601 491 410
Deposits & Other Assets 95 95 103 87 80
Total Assets 12,299 13,502 17,776 12,973 8,009
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 145 135 142 139 107
Current Portion Long-Term Debt 0 0 0 2 426
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 140 195 277 223 180
Income Taxes Payable 36 32 46 57 36
Other Current Liabilities 162 170 179 174 121
Total Current Liabilities 523 569 681 632 906
Mortgages 0 0 0 0 0
Deferred Taxes/Income 1,476 1,770 3,059 2,077 998
Convertible Debt 0 0 0 0 0
Long-Term Debt 1,199 1,198 11 12 14
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 195 196 182 197 161
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 3,558 3,886 4,109 3,093 2,254
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 449 447 442 429 410
Retained Earnings 9,261 9,898 13,507 9,268 5,471
Other Equity -336 -467 -176 282 -87
Treasury Stock 633 264 106 100 38
Total Shareholder's Equity 8,741 9,615 13,667 9,880 5,755
Total Liabilities & Shareholder's Equity 12,299 13,502 17,776 12,973 8,009
Total Common Equity 8,741 9,615 13,667 9,880 5,755
Shares Outstanding 28.50 29.60 29.90 29.80 29.90
Book Value Per Share 306.71 324.84 457.09 331.54 192.48

Fiscal Year End for BioRad Laboratories, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 1,613 1,765 1,728 1,857
Receivables NA 489 457 492 498
Notes Receivable NA 0 0 0 0
Inventories NA 781 776 777 753
Other Current Assets NA 166 149 142 169
Total Current Assets NA 3,048 3,147 3,139 3,277
Net Property & Equipment NA 529 511 514 506
Investments & Advances NA 7,698 7,218 7,311 8,879
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 734 721 740 736
Deposits & Other Assets NA 95 98 100 96
Total Assets NA 12,299 11,896 11,978 13,667
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 145 112 150 161
Current Portion Long-Term Debt NA 0 0 0 1
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 140 155 155 174
Income Taxes Payable NA 36 104 74 51
Other Current Liabilities NA 162 148 166 167
Total Current Liabilities NA 523 558 582 590
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 1,476 1,370 1,402 1,770
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 1,199 1,199 1,198 1,198
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 186 202 199
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 3,558 3,480 3,531 3,904
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 449 439 474 463
Retained Earnings NA 9,261 8,911 8,805 9,967
Other Equity NA -336 -498 -373 -408
Treasury Stock NA 633 437 459 258
Total Shareholder's Equity NA 8,741 8,416 8,447 9,764
Total Liabilities & Shareholder's Equity NA 12,299 11,896 11,978 13,667
Total Common Equity 0 8,741 8,416 8,447 9,764
Shares Outstanding 28.50 28.50 29.10 29.00 29.60
Book Value Per Share 0.00 306.71 289.22 291.27 329.86